Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Authors: Myung‐Ju Ahn, Ji‐Youn Han, Ki Hyeong Lee, Sang-We Kim, Dong‐Wan Kim, Yun‐Gyoo Lee, Eun Kyung Cho, Joo-Hang Kim, Gyeong‐Won Lee, Jong Seok Lee, Young Joo Min, Jin-Soo Kim, Sung Sook Lee, Hye Ryun Kim, Min Hee Hong, Jin Seok Ahn, Jong‐Mu Sun, Heung Tae Kim, Ki Hyeong Lee, Sohee Kim, Byoung Chul Cho - The Lancet 2019 cited by 135